Clinical Decision-Making in Pharmacology
Start from one idea: a drug is a deliberate poisoning aimed at a target. Every medicine works because it perturbs a biological process, and the same perturbation that helps can harm. Prescribing is therefore never "is this drug good or bad?" It is always a wager — the expected benefit of hitting the target must outweigh the expected harm of everything else the drug touches, in this patient, at this moment. Clinical pharmacology is the discipline that makes that wager explicit and defensible.
Everything else in this chapter is built on that single sentence. A drug helps because it reaches a target at a useful concentration; it harms because that concentration also reaches off-target tissues, the placenta, the fetus, or the breastfeeding infant; and the net of help minus harm depends on who the patient is, what disease she has, what else she is taking, and when in pregnancy she is exposed. Take that apart in order and a safe decision falls out.
In O&G the "patient" is rarely one person. The same dose may simultaneously act on a woman, an embryo or fetus, the placenta, a breastfeeding infant, a neonate adapting to extrauterine life, and — through monitoring and follow-up needs — a whole health system. The Primary candidate must be able to move from the first principle above to a safe decision along a fixed chain:
indication -> patient factors -> drug factors -> pregnancy/lactation context -> interactions -> monitoring -> safety-net -> review or stop
This chapter is deliberately foundational. It does not reproduce full clinical protocols for hypertension, sepsis, epilepsy, diabetes, HIV, contraception or postpartum haemorrhage. Those belong in the linked Intermediate and Final chapters. Here the aim is to build the prescribing reasoning — the mechanism of the decision itself — that makes those protocols intelligible rather than memorised.
The Prescribing Equation
Every prescription should be defensible in one sentence:
I am using this drug, for this indication, in this patient, at this dose and route, because the expected benefit exceeds the expected harm, and I will monitor these endpoints.
| Decision component | Question | O&G example |
|---|---|---|
| Indication | What disease process or prevention target am I treating? | Severe hypertension, uterine atony, HIV, sepsis, VTE risk |
| Urgency | Is delay more dangerous than uncertainty? | Maternal sepsis and eclampsia require immediate treatment |
| Patient physiology | Pregnancy, postpartum, renal, hepatic, weight, age, allergy, comorbidity? | Magnesium in oliguria is different from magnesium with normal urine output |
| Drug mechanism | What target creates benefit and toxicity? | Ergometrine contracts uterus but can worsen hypertension |
| Exposure | Will route, absorption, Vd, metabolism and elimination achieve target? | Oral therapy may fail in vomiting or shock |
| Pregnancy/lactation | Which fetal or infant vulnerability window applies? | First-trimester organogenesis differs from third-trimester neonatal adaptation |
| Interactions | Will other drugs or diseases change exposure or effect? | TB drugs, antiretrovirals, anticonvulsants and contraception |
| Monitoring | What proves benefit or toxicity? | BP, urine output, reflexes, renal function, cultures, glucose |
| Endpoint | When will I stop, switch or review? | Antibiotic review at 24-72 hours; postpartum insulin dose reassessment |
The common unsafe pattern is a prescription with no endpoint. "Continue" is not a plan unless it includes what is being continued for, what target is expected, what toxicity is being watched and when the decision will be revisited.
How a Drug Reaches Its Target
Before any of the decision components can be reasoned about, one mechanism must be clear, because it underlies most of the rest of the chapter: benefit and toxicity both depend on the concentration of free drug at a target over time. A correct indication and a correct mechanism still fail if the drug never reaches a useful concentration, or if it accumulates to a toxic one.
That concentration is governed by what the body does to the drug — its pharmacokinetics — captured in four steps:
- Absorption determines how much drug enters the circulation and how fast. Oral therapy can fail entirely in a vomiting or shocked patient because the gut is not absorbing; this is why an unstable woman with sepsis or eclampsia is treated by the intravenous route, not by tablets.
- Distribution (volume of distribution, Vd) describes how widely the drug spreads into tissue versus staying in plasma. It depends on lipid solubility and on protein binding — acidic drugs ride on albumin, basic drugs on α1-acid glycoprotein. Only the unbound fraction is pharmacologically active and able to cross membranes, including the placenta.
- Metabolism, mostly hepatic, converts drug into more water-soluble metabolites for excretion (cytochrome-P450 oxidation and conjugation reactions). The same enzymes are the site of most clinically important drug interactions.
- Elimination, mostly renal, clears drug and active metabolites. A renally cleared drug accumulates when the kidney fails.
Pregnancy quietly changes every one of these steps, which is why "the usual dose" is not automatically the right dose in a pregnant woman. Plasma volume and total body water rise, so the volume of distribution increases; serum albumin falls, so the free fraction of albumin-bound drugs rises; renal plasma flow and glomerular filtration increase, so renally cleared drugs may be eliminated faster and run sub-therapeutic; hepatic enzyme activity shifts in both directions; and delayed gastric emptying alters the rate of oral absorption. The placenta adds a further compartment — lipid-soluble, unbound, low-molecular-weight drugs cross most readily, and the fetus then has its own immature liver and kidney handling them. None of this is trivia: it is exactly why some antiseizure or antiretroviral levels drift in pregnancy, why a "normal" serum creatinine can mask real renal impairment, and why a drug safe at one gestation may not be at another. Later sections return to each of these consequences; the point here is that they all flow from one chain — absorption, distribution, metabolism, elimination of free drug at a target.
Start with Indication, Not Habit
Drug decisions should begin with the problem, not the medicine cupboard. A drug can be perfect for one indication and harmful in another.
| Presentation | Poor question | Better pharmacology question |
|---|---|---|
| Postpartum haemorrhage | Which uterotonic do I usually give next? | What is the cause of bleeding, and which mechanism addresses it? |
| Severe pre-eclampsia | Which drug lowers BP fastest? | What prevents stroke, what prevents seizures, and what preserves perfusion? |
| Fever after caesarean | Which antibiotic is strongest? | Is this infection, where is the source, and what organisms need early cover? |
| Vomiting in pregnancy | Which antiemetic is safest? | Is there dehydration, ketonuria, thiamine deficiency risk, electrolyte disturbance or alternate diagnosis? |
| Chronic disease medication | Should everything stop because she is pregnant? | What is the untreated disease risk versus exposure risk at this gestation? |
The chain for any clinical stem is:
diagnosis and severity -> pathophysiology -> drug target -> expected clinical effect -> predictable toxicity -> monitoring
If the diagnosis is uncertain and the patient is stable, better assessment may be safer than empirical prescribing. If the patient is unstable, immediate treatment may be safer than waiting for diagnostic certainty. Clinical pharmacology is therefore not slow; it is structured.